Baidu
map

盘点:近期胃食管反流研究进展一览

2017-03-03 MedSci MedSci原创

胃食管反流病(GERD),是一种极为常见的疾病,在西方国家成人中的发病率为10%-20%。越来越多的研究已经证明了身体质量指数增加和胃酸反流症状恶化之间的直接联系。胃食管反流患可能会影响越来越多的人。随着肥胖情况日益严重严重,胃食管反流病可能更加流行。尽管治疗胃食管反流病的非处方疗法很多,持续或预警症状应始终及时咨询医生。本文小编汇总了近期胃食管反流亮点研究,与大家分享。【1】Stretta射

胃食管反流病(GERD),是一种极为常见的疾病,在西方国家成人中的发病率为10%-20%。越来越多的研究已经证明了身体质量指数增加和胃酸反流症状恶化之间的直接联系。胃食管反流患可能会影响越来越多的人。随着肥胖情况日益严重严重,胃食管反流病可能更加流行。尽管治疗胃食管反流病的非处方疗法很多,持续或预警症状应始终及时咨询医生。本文小编汇总了近期胃食管反流亮点研究,与大家分享。


根据近期一项系统回顾和荟萃分析的结果,使用Stretta程序的内镜下射频治疗对胃食管反流病(GERD)有效且安全。相关内容在线发表于Surgical Endoscopy上。

Metro健康医学中心Ronnie Fass博士说:“这项研究的结果表明Stretta显着减少GERD症状,同时也影响生理参数,如减少酸暴露、愈合糜烂性食管炎。”Fass和同事,包括Frederick Cahn博士,进行了生物医学文献搜索,纳入28项研究(包括4项随机控制试验,23项队列研究和1项注册研究),涉及2468例接受Stretta治疗的患者。提供了10年随访数据(平均随访25.4个月)。Stretta明显改善健康相关生活质量和烧心,有一半患者在Stretta治疗后可停止使用PPI。此外,Stretta使糜烂性食管炎的发生率降低24%,在固定效应模型达到意义,并能显着减少食管酸暴露。

然而,对食管下括约肌基底压的改善没有显着优于假手术组。不良事件的发生率,Stretta为0.93%,腹腔镜下胃底折术为7.18%。小的糜烂和黏膜撕裂是Stretta最常见的不良事件(<1%)。这项荟萃分析的优势包括随访数据跨度长达10年,并且纳入研究的患者人数众多。结果表明,Stretta是一种治疗GERD的安全有效的方法。

此外,去年发表在Managed上的预算影响分析显示,Stretta疗法与长期药物或手术方法相比,能节约大量成本。


胃食管反流症状在社区人群中很是常见,但一直没有明确的针对所有估计胃食管反流症状全球患病率或该病潜在的危险因素的研究数据进行系统评价和荟萃分析。近日,消化病领域权威杂志gut上发表了一篇针对这一问题的荟萃分析文章。

研究人员通过检索MEDLINE、EMBASE和EMBASE经典数据库(检索时间直到2016年9月),确定了报道了成人(≥15岁)胃食管反流症状发生率以人群为基础的研究;胃食管反流的确诊是通过使用基于症状的标准或问卷来完成。研究人员从所有研究中提取患病率,并根据使用的标准来进行定义。根据研究的位置和其他一些特点,将患病率进行合并,并计算比值比和95%可信区间。

研究人员评估了14132篇文献,有102篇文献在108个不同的研究人群中报道了胃食管反流症状的发生率,含有460984例患者。患病率根据国家(从中国的2.5%到希腊的51.2%)和用来确定胃食管反流症状的标准而有所不同。只有当研究采用每周烧心或反流频率来定义胃食管反流症状才被考虑,合并的患病率为13.3%(95%可信区间为12%-14.6%)。在年龄≥50岁(比值比为1.32;95%可信区间为1.12-1.54)、吸烟者(比值比为1.26;95%可信区间为1.04-1.52)、非甾体类抗炎药(NSAID)/阿司匹林使用者(比值比为1.44;95%可信区间为1.10-1.88)和肥胖(比值比为1.73;95%可信区间为1.46-2.06)的受试者中患病率较高。

由此可见,胃食管反流症状的发生率在国家之间存在明显的不同,即使采用类似的定义来定义胃食管反流症状的存在。在年龄≥50岁、吸烟者、非甾体抗炎药使用者和肥胖的个体中患病率较高,虽然这些相关性较为中等。


胃食管反流病(gastroesophageal reflux disease,GERD)是指胃内容物反流入食管引起的反流相关症状和(或)并发症的一种疾病。GERD在西方国家十分常见,近10年来中国人群的GERD患病率持续上升。

近期,Current Opinion in Gastroenterology杂志上一篇文章对饮食和GERD之间的关系进行分析。

研究发现:随着药物治疗、副作用和广泛地过度应用的意识在GERD管理方面增加,非药物治疗引起了学者们的关注。目前已经有研究确定了营养学在GERD症状管理上起着重要作用。已知某些食物例如柑橘、酒、碳酸饮料可以恶化GERD症状。某些触发回流食物已经获得了科学证据的支持,也提供了一些相关数据,这些食物包括脂肪、油炸食品和饮料等。一些人群研究提示通过遵循特定膳食可以减轻反流症状。肥胖也会与GERD症状增加有关。反过来,BMI降低会减轻反流症状。此外,一些重要生活方式调整例如抬高床头和延长吃饭与睡觉之间的时间,可以为有效控制GERD症状提供非药物技术。

GERD的诊断和管理是昂贵的,药物治疗可能会带来相应的不良反应。这篇文章突出了饮食对GERD管理的重要性,通过避免某些食物的有效饮食调整和生活方式改变可能改善疾病控制,同时预防并发症。


目前,组织学标准被细化用于诊断胃食管反流病(GERD)。消化病领域权威杂志《Clinical
Gastroenterology and Hepatology》发表了一篇研究文章,旨在评估食管上皮厚度在GERD诊断的作用。

在欧洲和加拿大的成年人群中,研究者征集以经常出现上消化道症状并且未服用质子泵抑制剂的患者为研究对象进行Diamond研究(NCT 00291746),并对Diamond研究的数据进行了深入挖掘。GERD的诊断基于以下1个或更多的临床表现:反流性食管炎、胃酸暴露的病理性食管和/或胃酸相关的阳性症状。非糜烂性反流病诊断依据为胃酸暴露的病理性食管和/或胃酸相关的阳性症状,但无反流性食管炎。研究者收集和评估了336例患者Z线0.5厘米和2厘米以上的活检结果,通过德国和意大利的活检病理中心(分别为258例和195例)进行独立分析。主要指标是GERD的组织学诊断标准的准确性,通过内镜和pH监测来确定。

研究者发现:基底细胞层增厚的位置以及总上皮厚度是诊断GERD的最佳的诊断标准;它还明确了Z线0.5厘米和2厘米以上的非糜烂性反流病、反流性食管炎以及胃酸暴露的病理性食管情况。基底细胞层厚度和存在扩张的细胞内间隙并不能诊断为GERD。在测试的诊断标准中,两个活检病理中心给出的最好的诊断指标是评估Z线0.5厘米和2厘米以上总上皮厚度。

由此可见,基于336例经常出现上消化道症状患者的数据分析,总上皮厚度是诊断GERD的一个很重要组织学标志。


非洲裔美国女性与欧裔美国女性相比,虽然肥胖率更高;但是胃食管反流病(GERD)及其合并症却在欧裔美国女性中更为普遍。随着肥胖的增加,随之而来是胰岛素抵抗,进而饮食中过量摄入大量营养素,导致女性更多的GERD患病率和更严重的病情。

目的:探究GERD是否与饮食中碳水化合物的摄入量有关,特别是膳食简单的碳水化合物摄入,以及GERD是否与胰岛素抵抗有关。

方法:研究纳入了144名肥胖女性,在基线、以及摄入高脂肪/低碳水化合物饮食16周后,对参与者进行评估。通过症状医疗记录、药物使用情况,每周对参与者的GERD诊断和相关药物进行评估。

结果:约33.3% (N = 33)的欧裔美国女性和20.0% (N = 9)的非洲裔美国女性,在基线时就存在GERD。与GERD相关的因素有:总碳水化合物(r = 0.34, P < 0.001)、糖(r = 0.30, P = 0.005)、血糖负荷(r = 0.34, P = 0.001)和HOMAIR (r = 0.30, P = 0.004);注意,这些关联仅限于欧裔美国女性。至于高脂肪/低碳水化合物饮食,减少糖的摄入量与胰岛素抵抗的下降有关。在第10周饮食结束时,所以女性中GERD症状和药物使用情况得到缓解。

结论:GERD症状和药物使用情况在欧裔美国女性中更常见;对于这类女性,饮食中碳水化合物的摄入量、胰岛素抵抗和GERD之间存在相关性。不管怎样,高脂肪/低碳水化合物饮食可以缓解所有女性的GERD症状和药物使用情况。


发表在《JAMA》杂志上的一项试验,为了研究急性GERD的发病机制对急性GERD食管炎症的组织学特征进行了评估。

来自达拉斯退伍军人事务(Dallas Veterans Affairs)医学中心的患者患有反流性食管炎,经质子泵抑制剂(PPIs)获得成功治疗,在基线(服用PPIs)和停止PPI药物治疗后1周和2周时,他们开始24-小时食管pH和阻抗监测以及联合从远端食管非糜烂区域采集活检的食管镜检查(包括共聚焦激光显微内镜[CLE])。招募开始于2013年5月,随访结束至2015年7月。干预措施是PPI停止2周。

一共有12例(男性:11例;平均年龄,57.6岁[SD,13.1])患者完成了研究。主要终点是停止PPI药物治疗后2周食管活检下食管炎症的变化,通过比较淋巴细胞,嗜酸性粒细胞,和中性粒细胞浸润确定(每种以0-3级计分)。此外,还对上皮基底细胞变化和乳头状增生,表明糜烂,细胞间隙宽度,食管炎内镜分级,食管酸暴露,以及黏膜阻抗(一种黏膜完整性指标)进行评估。

PPI停药后1周和2周时,活检显示上皮内淋巴细胞显著增加,以T细胞(中位数[范围]:基线0(0-2)vs 1周[P=0.005]和2周时[P=0.002]1(1-2))为主;中性粒细胞和嗜酸性粒细胞很少或没有。活检还显示,细胞间隙变宽(由CLE确认),以及基底细胞和乳头状增生进展,不伴有表面糜烂。停止PPI药物治疗后2周,食管酸暴露增加(中位数:基线时1.2%,2周时,17.8%;Δ,16.2%[95%CI,4.4%-26.5%],P =0 .005),黏膜阻抗降低(中位值:基线时2671.3 Ω,2周时1508.4 Ω;Δ,1162.9 Ω [95%CI,629.9-1695.9],P =0 .001),所有患者均有食管炎证据。

在12例严重反流性食管炎患者经PPI方案成功治疗的这些初步研究中,停止PPI药物治疗会带来以T-淋巴细胞为主的食管炎症和不伴有表面细胞损失的基底细胞和乳头状增生。如果能被复制,这些研究结果提示反流性食管炎的发病机制可能是细胞因子介导而非化学损伤的结果。


发表在British Journal of Surgery study的研究称,腹腔镜手术治疗胃食管反流性疾病,术后死亡率和需要再次进行手术的可能性均非常低。

研究者对8947名胃食管反流性疾病患者进行了腹腔镜手术,术后90天和30天的死亡率仅为0.08%和0.03%。并且死亡案例中只有1例其死于与手术相关。此外,术后90天内再次手术发生率仅为0.4%。

研究结果表明,对于胃食管反流性疾病患者,腹腔镜手术是可以替代药物治疗的安全的治疗方式。

研究作者John Maret-Ouda博士说:“对于抗反流手术,反对者中有一个理由是,手术会带来死亡风险。不过,当前我们的研究发现,抗反流手术是安全的,它可能是胃食管反流性疾病患者未被充分利用的治疗选择。”


近期发表于JAMA,研究称造成胃食管反流病(GERD)的原因可能是由于免疫反应的损伤而非胃酸反流导致的化学性损伤。

该研究的第一作者、德克萨斯州的退伍军人医疗中心的Kerry Dunbar博士和其同事称:“在研究初期,PPI成功治愈了患有严重胃食管反流病的12名患者,而PPI的停用与T淋巴细胞主导的食管炎症、基底细胞和乳头状增生无表面细胞丢失有关。”

他们补充,“如果能成功复制这个模型,那可能提示反流性食管炎的病因可能是由于细胞因子介导的损伤而非胃酸导致的化学性损伤”。

该研究纳入了退伍军人医疗中心的患有严重胃食管反流病的12例患者(11例为男性,平均年龄57.6岁),他们都成功的被PPI治愈。在基线水平时,所有研究对象均停用PPI制剂并接受评估,并在停药1周及2周后再次接受评估。评估包括24小时食管pH监测及阻抗监测(反映粘膜完整性的指数)和食管镜(包括高分辨率激光共聚焦纤维内镜)。研究者取患者食管未被损伤的区域进行活检,发现其免疫活性低于受损伤的区域。

在基线水平,几乎所有研究对象(11/12)都没有明显的食管炎的证据,但在停用PPI2周后,所有研究对象均发展为食管炎,其中5例为严重食管炎。

在2周的研究期间,所有研究对象都出现了GERD的异常特征:基底细胞和乳头增生(P<0.01),乳头延长(P<0.01),食管鳞状上皮的细胞间隙增宽(P<0.001),粘膜阻抗减少(P=0.001),食管远端酸暴露增加。从基线至2周时,酸暴露增加了16.2%(95%可信区间,26.5%-4.4%;P=0.005)。

淋巴细胞浸润与粒细胞浸润的不同

活检结果显示停用1周及2周PPI后上皮内淋巴细胞浸润显著增加,并且表现为T淋巴细胞优势型(1周时,P =0.005;2周时,P =0.002)以及中性粒细胞和嗜酸性粒细胞减少或缺失。

“表面没有糜烂的区域出现了食管基底细胞和乳头增生。如果传统的观念,即急性GERD是由于胃酸回流引起表皮细胞的化学损伤是正确的,那么基底细胞和乳头增生本应该仅出现在表面糜烂区,浸润的炎性细胞则应是粒细胞为主,”作者写道。他们还需要进一步的研究来证实这些结果。

芝加哥西北大学费因伯格医学院的博士Peter Kahrilas认为,“这项研究的结果显示:最早的病理变化发生在上皮细胞,而不是在粘膜表面,在表面的细胞死亡之前,机体修复开始启动,从而导致了这些变化。”

“尽管这个刺激的病理生理变化无疑是胃和十二指肠分泌物回流到食道引起的,但是证据表明,回流的影响引发了炎症细胞因子的启动,而不像以往认识到的是酸、胃蛋白酶和胆汁直接对食管上皮细胞化学作用。”他写道。

研究的局限性和前景

他指出,在这项研究中的患者患有严重的GERD和食管裂孔疝,可能代表了所有GERD患者的1%-5%,因此这一结果可能并不适用于所有的GERD患者。然而,这一结果让人们将注意力从胃酸的“烧灼”作用转向免疫反应,这可能有助于解释最近被发现的胃食管反流病的亚型。

他还指出,研究结果还可能对治疗有一定的影响。虽然PPI仍然会是继续治疗的中坚力量,但炎症级联反应的发现可能成为新治疗的靶点,该治疗可能对于患有更严重或难治性胃食管反流病的患者有效。

“基于这些发现,也许难治性GERD应该根据临床表现和疾病进展分步治疗,”他说,“这个疾病有着多种多样的病人,治疗难题只能一块一块解决。Dunbar等人可能解决了非常重要的一块。”

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (57)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1948530, encodeId=f507194853056, content=<a href='/topic/show?id=87828339e7a' target=_blank style='color:#2F92EE;'>#胃食管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83397, encryptionId=87828339e7a, topicName=胃食管)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Thu Jun 01 04:16:00 CST 2017, time=2017-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190362, encodeId=74e01903627f, content=不断学习不断进步, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Tue Apr 25 07:14:37 CST 2017, time=2017-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=187112, encodeId=2e9d18e11225, content=继续努力锲而不舍, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Thu Apr 13 12:33:51 CST 2017, time=2017-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=186925, encodeId=3f7618692587, content=不断学习不断进步, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Wed Apr 12 19:24:24 CST 2017, time=2017-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=186328, encodeId=7e4d1863287e, content=不断学习不断进步, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Mon Apr 10 06:54:27 CST 2017, time=2017-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185665, encodeId=756618566544, content=胃食管反流的新进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Fri Apr 07 06:25:40 CST 2017, time=2017-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185613, encodeId=708a185613fc, content=继续努力锲而不舍, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Thu Apr 06 21:51:02 CST 2017, time=2017-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185323, encodeId=f1cd1853232d, content=胃食管反流的新进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Wed Apr 05 13:40:57 CST 2017, time=2017-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185040, encodeId=cefc18504073, content=胃食管反流的新进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Tue Apr 04 07:59:45 CST 2017, time=2017-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=184873, encodeId=820c1848e3c8, content=学海无涯苦作舟, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Mon Apr 03 14:43:27 CST 2017, time=2017-04-03, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1948530, encodeId=f507194853056, content=<a href='/topic/show?id=87828339e7a' target=_blank style='color:#2F92EE;'>#胃食管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83397, encryptionId=87828339e7a, topicName=胃食管)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Thu Jun 01 04:16:00 CST 2017, time=2017-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190362, encodeId=74e01903627f, content=不断学习不断进步, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Tue Apr 25 07:14:37 CST 2017, time=2017-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=187112, encodeId=2e9d18e11225, content=继续努力锲而不舍, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Thu Apr 13 12:33:51 CST 2017, time=2017-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=186925, encodeId=3f7618692587, content=不断学习不断进步, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Wed Apr 12 19:24:24 CST 2017, time=2017-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=186328, encodeId=7e4d1863287e, content=不断学习不断进步, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Mon Apr 10 06:54:27 CST 2017, time=2017-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185665, encodeId=756618566544, content=胃食管反流的新进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Fri Apr 07 06:25:40 CST 2017, time=2017-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185613, encodeId=708a185613fc, content=继续努力锲而不舍, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Thu Apr 06 21:51:02 CST 2017, time=2017-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185323, encodeId=f1cd1853232d, content=胃食管反流的新进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Wed Apr 05 13:40:57 CST 2017, time=2017-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185040, encodeId=cefc18504073, content=胃食管反流的新进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Tue Apr 04 07:59:45 CST 2017, time=2017-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=184873, encodeId=820c1848e3c8, content=学海无涯苦作舟, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Mon Apr 03 14:43:27 CST 2017, time=2017-04-03, status=1, ipAttribution=)]
    2017-04-25 1e104401m00(暂无匿称)

    不断学习不断进步

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1948530, encodeId=f507194853056, content=<a href='/topic/show?id=87828339e7a' target=_blank style='color:#2F92EE;'>#胃食管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83397, encryptionId=87828339e7a, topicName=胃食管)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Thu Jun 01 04:16:00 CST 2017, time=2017-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190362, encodeId=74e01903627f, content=不断学习不断进步, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Tue Apr 25 07:14:37 CST 2017, time=2017-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=187112, encodeId=2e9d18e11225, content=继续努力锲而不舍, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Thu Apr 13 12:33:51 CST 2017, time=2017-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=186925, encodeId=3f7618692587, content=不断学习不断进步, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Wed Apr 12 19:24:24 CST 2017, time=2017-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=186328, encodeId=7e4d1863287e, content=不断学习不断进步, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Mon Apr 10 06:54:27 CST 2017, time=2017-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185665, encodeId=756618566544, content=胃食管反流的新进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Fri Apr 07 06:25:40 CST 2017, time=2017-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185613, encodeId=708a185613fc, content=继续努力锲而不舍, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Thu Apr 06 21:51:02 CST 2017, time=2017-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185323, encodeId=f1cd1853232d, content=胃食管反流的新进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Wed Apr 05 13:40:57 CST 2017, time=2017-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185040, encodeId=cefc18504073, content=胃食管反流的新进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Tue Apr 04 07:59:45 CST 2017, time=2017-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=184873, encodeId=820c1848e3c8, content=学海无涯苦作舟, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Mon Apr 03 14:43:27 CST 2017, time=2017-04-03, status=1, ipAttribution=)]
    2017-04-13 1e104401m00(暂无匿称)

    继续努力锲而不舍

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1948530, encodeId=f507194853056, content=<a href='/topic/show?id=87828339e7a' target=_blank style='color:#2F92EE;'>#胃食管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83397, encryptionId=87828339e7a, topicName=胃食管)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Thu Jun 01 04:16:00 CST 2017, time=2017-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190362, encodeId=74e01903627f, content=不断学习不断进步, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Tue Apr 25 07:14:37 CST 2017, time=2017-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=187112, encodeId=2e9d18e11225, content=继续努力锲而不舍, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Thu Apr 13 12:33:51 CST 2017, time=2017-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=186925, encodeId=3f7618692587, content=不断学习不断进步, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Wed Apr 12 19:24:24 CST 2017, time=2017-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=186328, encodeId=7e4d1863287e, content=不断学习不断进步, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Mon Apr 10 06:54:27 CST 2017, time=2017-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185665, encodeId=756618566544, content=胃食管反流的新进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Fri Apr 07 06:25:40 CST 2017, time=2017-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185613, encodeId=708a185613fc, content=继续努力锲而不舍, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Thu Apr 06 21:51:02 CST 2017, time=2017-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185323, encodeId=f1cd1853232d, content=胃食管反流的新进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Wed Apr 05 13:40:57 CST 2017, time=2017-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185040, encodeId=cefc18504073, content=胃食管反流的新进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Tue Apr 04 07:59:45 CST 2017, time=2017-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=184873, encodeId=820c1848e3c8, content=学海无涯苦作舟, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Mon Apr 03 14:43:27 CST 2017, time=2017-04-03, status=1, ipAttribution=)]
    2017-04-12 1e104401m00(暂无匿称)

    不断学习不断进步

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1948530, encodeId=f507194853056, content=<a href='/topic/show?id=87828339e7a' target=_blank style='color:#2F92EE;'>#胃食管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83397, encryptionId=87828339e7a, topicName=胃食管)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Thu Jun 01 04:16:00 CST 2017, time=2017-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190362, encodeId=74e01903627f, content=不断学习不断进步, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Tue Apr 25 07:14:37 CST 2017, time=2017-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=187112, encodeId=2e9d18e11225, content=继续努力锲而不舍, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Thu Apr 13 12:33:51 CST 2017, time=2017-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=186925, encodeId=3f7618692587, content=不断学习不断进步, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Wed Apr 12 19:24:24 CST 2017, time=2017-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=186328, encodeId=7e4d1863287e, content=不断学习不断进步, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Mon Apr 10 06:54:27 CST 2017, time=2017-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185665, encodeId=756618566544, content=胃食管反流的新进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Fri Apr 07 06:25:40 CST 2017, time=2017-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185613, encodeId=708a185613fc, content=继续努力锲而不舍, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Thu Apr 06 21:51:02 CST 2017, time=2017-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185323, encodeId=f1cd1853232d, content=胃食管反流的新进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Wed Apr 05 13:40:57 CST 2017, time=2017-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185040, encodeId=cefc18504073, content=胃食管反流的新进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Tue Apr 04 07:59:45 CST 2017, time=2017-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=184873, encodeId=820c1848e3c8, content=学海无涯苦作舟, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Mon Apr 03 14:43:27 CST 2017, time=2017-04-03, status=1, ipAttribution=)]
    2017-04-10 1e104401m00(暂无匿称)

    不断学习不断进步

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1948530, encodeId=f507194853056, content=<a href='/topic/show?id=87828339e7a' target=_blank style='color:#2F92EE;'>#胃食管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83397, encryptionId=87828339e7a, topicName=胃食管)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Thu Jun 01 04:16:00 CST 2017, time=2017-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190362, encodeId=74e01903627f, content=不断学习不断进步, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Tue Apr 25 07:14:37 CST 2017, time=2017-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=187112, encodeId=2e9d18e11225, content=继续努力锲而不舍, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Thu Apr 13 12:33:51 CST 2017, time=2017-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=186925, encodeId=3f7618692587, content=不断学习不断进步, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Wed Apr 12 19:24:24 CST 2017, time=2017-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=186328, encodeId=7e4d1863287e, content=不断学习不断进步, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Mon Apr 10 06:54:27 CST 2017, time=2017-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185665, encodeId=756618566544, content=胃食管反流的新进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Fri Apr 07 06:25:40 CST 2017, time=2017-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185613, encodeId=708a185613fc, content=继续努力锲而不舍, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Thu Apr 06 21:51:02 CST 2017, time=2017-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185323, encodeId=f1cd1853232d, content=胃食管反流的新进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Wed Apr 05 13:40:57 CST 2017, time=2017-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185040, encodeId=cefc18504073, content=胃食管反流的新进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Tue Apr 04 07:59:45 CST 2017, time=2017-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=184873, encodeId=820c1848e3c8, content=学海无涯苦作舟, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Mon Apr 03 14:43:27 CST 2017, time=2017-04-03, status=1, ipAttribution=)]
    2017-04-07 1e104401m00(暂无匿称)

    胃食管反流的新进展

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1948530, encodeId=f507194853056, content=<a href='/topic/show?id=87828339e7a' target=_blank style='color:#2F92EE;'>#胃食管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83397, encryptionId=87828339e7a, topicName=胃食管)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Thu Jun 01 04:16:00 CST 2017, time=2017-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190362, encodeId=74e01903627f, content=不断学习不断进步, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Tue Apr 25 07:14:37 CST 2017, time=2017-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=187112, encodeId=2e9d18e11225, content=继续努力锲而不舍, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Thu Apr 13 12:33:51 CST 2017, time=2017-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=186925, encodeId=3f7618692587, content=不断学习不断进步, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Wed Apr 12 19:24:24 CST 2017, time=2017-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=186328, encodeId=7e4d1863287e, content=不断学习不断进步, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Mon Apr 10 06:54:27 CST 2017, time=2017-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185665, encodeId=756618566544, content=胃食管反流的新进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Fri Apr 07 06:25:40 CST 2017, time=2017-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185613, encodeId=708a185613fc, content=继续努力锲而不舍, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Thu Apr 06 21:51:02 CST 2017, time=2017-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185323, encodeId=f1cd1853232d, content=胃食管反流的新进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Wed Apr 05 13:40:57 CST 2017, time=2017-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185040, encodeId=cefc18504073, content=胃食管反流的新进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Tue Apr 04 07:59:45 CST 2017, time=2017-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=184873, encodeId=820c1848e3c8, content=学海无涯苦作舟, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Mon Apr 03 14:43:27 CST 2017, time=2017-04-03, status=1, ipAttribution=)]
    2017-04-06 1e104401m00(暂无匿称)

    继续努力锲而不舍

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1948530, encodeId=f507194853056, content=<a href='/topic/show?id=87828339e7a' target=_blank style='color:#2F92EE;'>#胃食管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83397, encryptionId=87828339e7a, topicName=胃食管)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Thu Jun 01 04:16:00 CST 2017, time=2017-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190362, encodeId=74e01903627f, content=不断学习不断进步, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Tue Apr 25 07:14:37 CST 2017, time=2017-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=187112, encodeId=2e9d18e11225, content=继续努力锲而不舍, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Thu Apr 13 12:33:51 CST 2017, time=2017-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=186925, encodeId=3f7618692587, content=不断学习不断进步, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Wed Apr 12 19:24:24 CST 2017, time=2017-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=186328, encodeId=7e4d1863287e, content=不断学习不断进步, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Mon Apr 10 06:54:27 CST 2017, time=2017-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185665, encodeId=756618566544, content=胃食管反流的新进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Fri Apr 07 06:25:40 CST 2017, time=2017-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185613, encodeId=708a185613fc, content=继续努力锲而不舍, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Thu Apr 06 21:51:02 CST 2017, time=2017-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185323, encodeId=f1cd1853232d, content=胃食管反流的新进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Wed Apr 05 13:40:57 CST 2017, time=2017-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185040, encodeId=cefc18504073, content=胃食管反流的新进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Tue Apr 04 07:59:45 CST 2017, time=2017-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=184873, encodeId=820c1848e3c8, content=学海无涯苦作舟, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Mon Apr 03 14:43:27 CST 2017, time=2017-04-03, status=1, ipAttribution=)]
    2017-04-05 1e104401m00(暂无匿称)

    胃食管反流的新进展

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1948530, encodeId=f507194853056, content=<a href='/topic/show?id=87828339e7a' target=_blank style='color:#2F92EE;'>#胃食管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83397, encryptionId=87828339e7a, topicName=胃食管)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Thu Jun 01 04:16:00 CST 2017, time=2017-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190362, encodeId=74e01903627f, content=不断学习不断进步, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Tue Apr 25 07:14:37 CST 2017, time=2017-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=187112, encodeId=2e9d18e11225, content=继续努力锲而不舍, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Thu Apr 13 12:33:51 CST 2017, time=2017-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=186925, encodeId=3f7618692587, content=不断学习不断进步, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Wed Apr 12 19:24:24 CST 2017, time=2017-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=186328, encodeId=7e4d1863287e, content=不断学习不断进步, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Mon Apr 10 06:54:27 CST 2017, time=2017-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185665, encodeId=756618566544, content=胃食管反流的新进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Fri Apr 07 06:25:40 CST 2017, time=2017-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185613, encodeId=708a185613fc, content=继续努力锲而不舍, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Thu Apr 06 21:51:02 CST 2017, time=2017-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185323, encodeId=f1cd1853232d, content=胃食管反流的新进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Wed Apr 05 13:40:57 CST 2017, time=2017-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185040, encodeId=cefc18504073, content=胃食管反流的新进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Tue Apr 04 07:59:45 CST 2017, time=2017-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=184873, encodeId=820c1848e3c8, content=学海无涯苦作舟, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Mon Apr 03 14:43:27 CST 2017, time=2017-04-03, status=1, ipAttribution=)]
    2017-04-04 1e104401m00(暂无匿称)

    胃食管反流的新进展

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1948530, encodeId=f507194853056, content=<a href='/topic/show?id=87828339e7a' target=_blank style='color:#2F92EE;'>#胃食管#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=83397, encryptionId=87828339e7a, topicName=胃食管)], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220519/c2ab253484ee4527a2d4e9589a4821ac/45de9bf494a54becb2ea4369c9d11e85.jpg, createdBy=7a3710, createdName=循证小兵, createdTime=Thu Jun 01 04:16:00 CST 2017, time=2017-06-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=190362, encodeId=74e01903627f, content=不断学习不断进步, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Tue Apr 25 07:14:37 CST 2017, time=2017-04-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=187112, encodeId=2e9d18e11225, content=继续努力锲而不舍, beContent=null, objectType=article, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Thu Apr 13 12:33:51 CST 2017, time=2017-04-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=186925, encodeId=3f7618692587, content=不断学习不断进步, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Wed Apr 12 19:24:24 CST 2017, time=2017-04-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=186328, encodeId=7e4d1863287e, content=不断学习不断进步, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Mon Apr 10 06:54:27 CST 2017, time=2017-04-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185665, encodeId=756618566544, content=胃食管反流的新进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Fri Apr 07 06:25:40 CST 2017, time=2017-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185613, encodeId=708a185613fc, content=继续努力锲而不舍, beContent=null, objectType=article, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Thu Apr 06 21:51:02 CST 2017, time=2017-04-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185323, encodeId=f1cd1853232d, content=胃食管反流的新进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Wed Apr 05 13:40:57 CST 2017, time=2017-04-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=185040, encodeId=cefc18504073, content=胃食管反流的新进展, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Tue Apr 04 07:59:45 CST 2017, time=2017-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=184873, encodeId=820c1848e3c8, content=学海无涯苦作舟, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=95d11946707, createdName=1e104401m00(暂无匿称), createdTime=Mon Apr 03 14:43:27 CST 2017, time=2017-04-03, status=1, ipAttribution=)]
    2017-04-03 1e104401m00(暂无匿称)

    学海无涯苦作舟

    0

相关资讯

2016CHEST指南——胃食管反流患者引起的慢性咳嗽发布

本文是对2006ACCP反流性咳嗽综合征临床实践指南的更新,指南小组成员通过使用一个诊断/治疗法则解决常见咳嗽的病因包括反流症状,2.改变生活方式以及减重可能对疑似反流性咳嗽综合征有益,单独使用PPIs未显示益处;3.难治性患者考虑抗反流手术或临床高度怀疑其中有需要进行诊断测试的患者可进行生理检测。 全文获取:下载地址:指南下载 (需要扣积分2分, 梅斯医学APP免积

盘点:近期胃食管反流指南共识一览

胃食管反流病(GERD),是一种极为常见的疾病,在西方国家成人中的发病率为10%-20%。越来越多的研究已经证明了身体质量指数增加和胃酸反流症状恶化之间的直接联系。胃食管反流患可能会影响越来越多的人。随着肥胖情况日益严重严重,胃食管反流病可能更加流行。尽管治疗胃食管反流病的非处方疗法很多,持续或预警症状应始终及时咨询医生。那么近期关于胃食管反流指南共识一览有哪些,梅斯医学小编为您盘点。【1】201

Br J Surg:胃食管反流,还可以手术治疗!

发表在British Journal of Surgery study的研究称,腹腔镜手术治疗胃食管反流性疾病,术后死亡率和需要再次进行手术的可能性均非常低。研究者对8947名胃食管反流性疾病患者进行了腹腔镜手术,术后90天和30天的死亡率仅为0.08%和0.03%。并且死亡案例中只有1例其死于与手术相关。此外,术后90天内再次手术发生率仅为0.4%。研究结果表明,对于胃食管反流性疾病患者,腹腔镜

BMC Gastroenterology:乳糜泻患者症状多不典型 医生需警惕

据意大利新近研究,经典的乳糜泻症状已不再出现于大多数新近确诊患者。相反,研究者表明医生应考虑乳糜泻可能出现的其他症状,即使患者并未在意。 哥伦比亚大学腹部疾病中心主任 Peter Green 医生说:“从1970年代以来,在成人和儿童中都出现经典腹泻症状者越来越少,而更多患者症状不典型,甚至无症状。我们并不确知一个患者腹泻而另一个却腹痛或者骨质疏松的原因。” 意大利博洛尼亚大学医学教授

盘点:有关胃食管反流研究一览

胃食管腔因过度接触(或暴露于)胃液而引起的临床胃食管反流症和食管黏膜损伤的疾病称为胃食管反流。胃食管反流及其并发症的发生是多因素的。其中包括食管本身抗反流机制的缺陷,如食管下括约肌功能障碍和食管体部运动异常等;也有食管外诸多机械因素的功能紊乱。2016年8月,腹部放射学会(SAR)疾病小组发布了胃食管反流病食管钡餐造影检查的共识声明,食管钡餐造影检查在胃食管反流病的检查中起的重要的作用,由于该

Baidu
map
Baidu
map
Baidu
map